Page 6 - Impact Factor News Today

Mandi : Indian Institute of Technology Mandi researchers have conducted a study to identify the most significant risk factors for cardiovascular diseases (CVDs) among adults aged 45 and above in India. CVDs are a leading cause of mortality worldwide,

Dec 23 (APP):Vice Chancellor of the State-run Mirpur University of Science and Technology (MUST), Mirpur, Brig. (Retd) Prof. Dr. Muhammad Younus Javed, (Sitara e Imtiaz Military) Thursday said that every fresh graduate of the MUST varsity, will, indeed, emerge as an ambassador of the varsity by con ..

Dr. Manel Esteller and Dr. Verónica Dávalos, researchers at the Josep Carreras Leukaemia Research Institute, describe in a new article the impact of epigenetics on cancer treatment and how it has become a crucial tool to improve early detection, predict disease progression and become a target for new treatments.

Heres whats wrong with the CDCs arbitrary 5-day isolation period recommendation for COVID.

EQS-News: ABIVAX / Key word(s): MiscellaneousABIVAX ABSTRACT ON OBEFAZIMOD PHASE 2B RESULTS SELECTED FOR MODERATED POSTER PRESENTATION AT UEG WEEK 2022 27.09.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax abstract on obefazimod phase 2b results selected for moderate...

Abivax abstract on obefazimod phase 2b results selected for moderated poster presentation at UEG Week 2022Obefazimod (ABX464) interim 48-week safety and efficacy analysis from the ongoing phase 2b maintenance

Në faqet e portaleve shqiptare të disa ditëve më parë por kryesisht nga lajmet e Top Channel dolën disa konstatime nga dr

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

DGAP-News: ABIVAX / Key word(s): Half Year Results Abivax presents first-half 2022 financial results and operations update 15....

DGAP-News: ABIVAX / Key word(s): Half Year ResultsAbivax presents first-half 2022 financial results and operations update 15.09.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.ABIVAX PRESENTS FIRST-HALF 2022 FINANCIAL RESULTS AND OPERATIONS UPDATE Obefazimod global piv...